



Proteomics International

LABORATORIES LTD

**ASX Release
22 August 2022**

ASX code: PIQ

Completion of Placement and Exercise of Performance Rights

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) advises that further to the ASX announcement of 15 August 2022, the Company has today completed Tranche 1 of the \$8.0 million placement to UK and Australian-based institutions, and sophisticated and professional investors (the "Placement").

The Company has issued 9,117,647 fully paid ordinary shares ("Shares") at an issue price of \$0.85 per Share pursuant to Tranche 1 of the Placement. The Shares were issued utilising the Company's 15% placement capacity under Listing Rule 7.1.

Subject to shareholder approval, Proteomics International Directors Neville Gardiner, Paul House and Roger Moore will participate in Tranche 2 of the Placement (total \$0.25m).

Morgans Financial Limited acted as Lead Manager to the Placement, Euroz Hartleys Securities Limited acted as Co-Manager and Candour Advisory acted as Corporate Advisor to the Placement.

Separately, the Company has today issued 23,295 Shares upon the exercise of unquoted performance rights. The performance rights were issued under the Performance Rights Plan as part of the incentive structures for key management personnel.

An Appendix 2A applying for quotation of the Shares has been lodged separately.

Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Shares noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- (c) as at the date of this Notice, there is no information:
 - i. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - II. that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
 - a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - b. the rights and liabilities attaching to the relevant Shares.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Eliot Graham
Manager, Corporate Advisory
Morgans Financial Limited
T: +61 3 9947 4101
E: eliot.graham@morgans.com.au

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com